Comparative Pharmacology
Head-to-head clinical analysis: IDAMYCIN PFS versus VALRUBICIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IDAMYCIN PFS versus VALRUBICIN.
IDAMYCIN PFS vs VALRUBICIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Idarubicin is an anthracycline antineoplastic antibiotic that intercalates with DNA and inhibits topoisomerase II, resulting in DNA strand breaks and inhibition of nucleic acid synthesis.
Anthracycline topoisomerase II inhibitor and DNA intercalator, causing DNA damage and cell death.
12 mg/m² intravenously over 10 to 15 minutes daily for 3 days (induction) or 12 mg/m² intravenously daily for 2 days (consolidation).
Intravesical instillation: 800 mg (4 vials of 200 mg/5 mL) diluted in 25 mL of 0.9% Sodium Chloride Injection, instilled into the bladder once weekly for 6 weeks. Retain in bladder for 1-2 hours.
None Documented
None Documented
Terminal elimination half-life of idarubicin is 20-30 hours; idarubicinol (active metabolite) has a terminal half-life of 45-60 hours, extending myelosuppression duration.
Clinical Note
moderateValrubicin + Digoxin
"Valrubicin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateValrubicin + Digitoxin
"Valrubicin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateValrubicin + Deslanoside
"Valrubicin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateValrubicin + Acetyldigitoxin
"Valrubicin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life is approximately 38 hours; clinically, it supports every-3-week dosing to avoid accumulation.
Renal (approximately 5-12% as unchanged drug and metabolites), biliary/fecal (significant, with 40-50% recovered in feces over 7 days).
Primarily hepatic metabolism and biliary excretion; renal excretion accounts for <5% of unchanged drug.
Category C
Category C
Anthracycline Antineoplastic
Anthracycline Antineoplastic